SYNH Syneos Health Inc. Class A

Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Syneos Health (SYNH) (Formerly INC Research Holdings, Inc.) and Encourages Investors to Contact the Firm Before January 30th

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired shares of Syneos Health (NASDAQ:SYNH) (formerly INC Research Holdings, Inc. (NASDAQ:INCR)) between May 10, 2017 and November 9, 2017 (the “Class Period”). Investors have until January 30, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Merger was not providing the benefit that Defendants stated it would; (2) that inVentiv was underperforming; (3) that, as a result, the Company's 2017 financial performance would be negatively impacted; and (4) that, as a result of the foregoing, Defendants’ statements about INC Research's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired INC Research securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the INC Research Holdings, Inc. lawsuit, please go to http://www.bespc.com/INCR. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
25/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Syneos Health Inc. Class A

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Syneos Health, Inc.: Update to credit analysis following review for do...

Syneos ratings are on review for downgrade following announcement that it was being acquired by an investment consortium for total purchase price of $7.1 billion, including its existing debt

Moody's places Syneos Health's ratings on review for downgrade on LBO ...

Moody's Investors Service (Moody's) placed Syneos Health, Inc.'s ("Syneos") ratings on review for downgrade. This follows an announcement that Syneos will be acquired by an investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital. The ratings pla...

Syneos Health, Inc.: Update following revision of outlook to negative

Syneos' credit profile reflects its good market position, moderate financial leverage, and strong liquidity, partially offset by operational headwinds.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch